Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Large Volume Increase – What’s Next?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) shares saw unusually-strong trading volume on Thursday. 166,025 shares were traded during trading, a decline of 13% from the previous session’s volume of 190,495 shares. The stock last traded at $29.49 and had previously closed at $30.00.

Analysts Set New Price Targets

LKFT has been the topic of several research reports. Royal Bank Of Canada raised Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $26.00 to $45.00 in a report on Wednesday, September 23rd. UBS Group raised shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 2nd. TD Cowen started coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, August 21st. They issued a “buy” rating on the stock. Finally, Morgan Stanley lowered their target price on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

Lakefront Biotherapeutics American Depositary Shares Price Performance

The company has a 50-day moving average of $28.42 and a two-hundred day moving average of $28.66. The stock has a market capitalization of $1.92 billion, a PE ratio of -20.67 and a beta of 0.24.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Monday, August 10th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.00. The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $7.29 million. On average, research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LKFT. ABC Arbitrage SA acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 1st quarter valued at about $248,000. QRG Capital Management Inc. boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after acquiring an additional 3,535 shares in the last quarter. Finally, Madison Avenue Partners LP lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 0.8% during the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock valued at $72,371,000 after buying an additional 17,394 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.